Safety and efficacy of triple combination therapy in hypertension and dyslipidemia: a systematic review and meta-analysis of randomized controlled trials
Triple therapy has greater effectiveness in decreasing blood pressure in hypertensive patients with dyslipidemia compared to treatments involving ARBs combined with amlodipine or ARBs with rosuvastatin. Additionally, Triple therapy significantly improved lipid profiles compared to the ARB/amlodipine group. Our study lays the groundwork for developing a single-pill, triple-combination therapy. Further RCTs are necessary to confirm our findings.
Authors
- Nourhan Ahmed
- Salem Badr (ORCID: https://orcid.org/0000-0002-7160-5010)
- Mariam Desouki
- Mahmoud Nassar (ORCID: https://orcid.org/0000-0002-5401-9562)
- Akram Y. Elgendy
- Ahmed Yasser Shaban
- D Hakim
- Malak A. Hassan
- Sherif Eltawansy
- Ahmed Hassan
Institutions
- University of Vermont (US)
- Brigham and Women's Hospital (US)
- Suez University (EG)
- Kafrelsheikh University (EG)
- University Hospitals of Cleveland (US)
- University Hospitals Cleveland Medical Center (US)
- Aurora St. Luke's Medical Center (US)
- Minneapolis Heart Institute Foundation (US)
- Ministry of Health and Population (EG)
- Jersey Shore University Medical Center (US)
- Alexandria University (EG)
Publication Details
- Journal
- The Egyptian Heart Journal
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1186/s43044-026-00720-z
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00